Portal de Periódicos da CAPES

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

2017; Baishideng Publishing Group; Volume: 23; Issue: 26 Linguagem: Inglês

10.3748/wjg.v23.i26.4675

2219-2840

Giulia Martini, Teresa Troiani, Claudia Cardone, Pietro Paolo Vitiello, Vincenzo Sforza, Davide Ciardiello, Stefania Napolitano, Carminia Maria Della Corte, Floriana Morgillo, Antonio Raucci, Antonio Cuomo, Francesco Selvaggi, Fortunato Ciardiello, Erika Martinelli,

Gastric Cancer Management and Outcomes

In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs.Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months.The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs.Only the RAS -mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with mCRC.In this review, we describe approved targeted therapies for the management of metastatic mCRC and discuss new candidate targets on the horizon.